AZNNYSEPharmaceutical PreparationsFiscal year ends December 31

ASTRAZENECA PLC

Financials through fiscal 2025, year ended Dec 31, 2025

$163.95−1.46 (-0.88%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 25.1
Dividend yield: 1.91%

Earnings

Quarterly results announced on Form 8-K, Item 2.02

No earnings releases found

Astrazeneca has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Press releases

Announcements Astrazeneca filed with the SEC

Nov 3, 2025, 12:36 PM ET
PUBLIC COMPANY LIMITED BY SHARES
EX-99.1 to Form 6-K

Where these numbers come from

Parsed from the XBRL in Astrazeneca's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-2 reverse split on Feb 2, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AZN.

Revenue growth8.6% · median 3.1%

Gross margin81.9% · median 71.7%

Net margin17.4% · median 18.9%

Company	Revenue	Growth
PFE	$63.70B	-0.2%
AZN	$58.74B	+8.6%
BMY	$49.19B	+3.1%
REGN	$15.53B	+9.3%
GSK	–	–
GMAB	–	–

Company

Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 901832

Advertisement
300 × 250